AGIOS PHARMACEUTICALS INC (AGIO) Fundamental Analysis & Valuation

NASDAQ:AGIO • US00847X1046

Current stock price

26.23 USD
-0.06 (-0.23%)
Last:

This AGIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. AGIO Profitability Analysis

1.1 Basic Checks

  • AGIO had negative earnings in the past year.
  • In the past year AGIO has reported a negative cash flow from operations.
  • In multiple years AGIO reported negative net income over the last 5 years.
  • In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • AGIO has a Return On Assets of -31.82%. This is in the better half of the industry: AGIO outperforms 62.21% of its industry peers.
  • AGIO has a better Return On Equity (-34.60%) than 70.93% of its industry peers.
Industry RankSector Rank
ROA -31.82%
ROE -34.6%
ROIC N/A
ROA(3y)-9.63%
ROA(5y)12.8%
ROE(3y)-11.43%
ROE(5y)13.77%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • AGIO has a Gross Margin of 88.26%. This is amongst the best in the industry. AGIO outperforms 89.53% of its industry peers.
  • AGIO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AGIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. AGIO Health Analysis

2.1 Basic Checks

  • AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AGIO has more shares outstanding than it did 1 year ago.
  • AGIO has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • AGIO has an Altman-Z score of 7.91. This indicates that AGIO is financially healthy and has little risk of bankruptcy at the moment.
  • AGIO's Altman-Z score of 7.91 is fine compared to the rest of the industry. AGIO outperforms 77.33% of its industry peers.
  • There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.91
ROIC/WACCN/A
WACC9.52%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 11.46 indicates that AGIO has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 11.46, AGIO belongs to the best of the industry, outperforming 83.53% of the companies in the same industry.
  • AGIO has a Quick Ratio of 11.06. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AGIO (11.06) is better than 83.14% of its industry peers.
Industry RankSector Rank
Current Ratio 11.46
Quick Ratio 11.06
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AGIO Growth Analysis

3.1 Past

  • The earnings per share for AGIO have decreased by -1.77% in the last year.
  • Looking at the last year, AGIO shows a very strong growth in Revenue. The Revenue has grown by 48.03%.
  • Measured over the past years, AGIO shows a very strong growth in Revenue. The Revenue has been growing by 55.97% on average per year.
EPS 1Y (TTM)-1.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.17%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y55.97%
Revenue growth 5YN/A
Sales Q2Q%86.39%

3.2 Future

  • Based on estimates for the next years, AGIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.68% on average per year.
  • Based on estimates for the next years, AGIO will show a very strong growth in Revenue. The Revenue will grow by 70.69% on average per year.
EPS Next Y5.2%
EPS Next 2Y12.26%
EPS Next 3Y14.71%
EPS Next 5Y14.68%
Revenue Next Year104.68%
Revenue Next 2Y135.4%
Revenue Next 3Y105.19%
Revenue Next 5Y70.69%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. AGIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AGIO. In the last year negative earnings were reported.
  • Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • AGIO's earnings are expected to grow with 14.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.26%
EPS Next 3Y14.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGIO Dividend Analysis

5.1 Amount

  • AGIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGIO Fundamentals: All Metrics, Ratios and Statistics

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (4/22/2026, 10:10:54 AM)

26.23

-0.06 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners103.25%
Inst Owner Change0.08%
Ins Owners1.04%
Ins Owner Change2.39%
Market Cap1.54B
Revenue(TTM)54.03M
Net Income(TTM)-412.78M
Analysts81.25
Price Target43.28 (65%)
Short Float %11.76%
Short Ratio7.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.2%
Min EPS beat(2)6.31%
Max EPS beat(2)8.09%
EPS beat(4)3
Avg EPS beat(4)6.13%
Min EPS beat(4)-4.68%
Max EPS beat(4)14.81%
EPS beat(8)5
Avg EPS beat(8)-32.85%
EPS beat(12)8
Avg EPS beat(12)-19.93%
EPS beat(16)12
Avg EPS beat(16)-4.36%
Revenue beat(2)2
Avg Revenue beat(2)42.22%
Min Revenue beat(2)21.22%
Max Revenue beat(2)63.21%
Revenue beat(4)3
Avg Revenue beat(4)25.5%
Min Revenue beat(4)-11.26%
Max Revenue beat(4)63.21%
Revenue beat(8)4
Avg Revenue beat(8)11.79%
Revenue beat(12)6
Avg Revenue beat(12)7.13%
Revenue beat(16)7
Avg Revenue beat(16)6.27%
PT rev (1m)6.07%
PT rev (3m)10.41%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)3.02%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)2.05%
Revenue NQ rev (1m)2.61%
Revenue NQ rev (3m)-10.36%
Revenue NY rev (1m)3.33%
Revenue NY rev (3m)-12.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.44
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-7.12
EYN/A
EPS(NY)-6.75
Fwd EYN/A
FCF(TTM)-6.44
FCFYN/A
OCF(TTM)-6.37
OCFYN/A
SpS0.92
BVpS20.36
TBVpS20.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -31.82%
ROE -34.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.26%
FCFM N/A
ROA(3y)-9.63%
ROA(5y)12.8%
ROE(3y)-11.43%
ROE(5y)13.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.37%
Cap/Sales 7.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.46
Quick Ratio 11.06
Altman-Z 7.91
F-Score3
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)42.75%
Cap/Depr(5y)49.48%
Cap/Sales(3y)5.44%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.17%
EPS Next Y5.2%
EPS Next 2Y12.26%
EPS Next 3Y14.71%
EPS Next 5Y14.68%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y55.97%
Revenue growth 5YN/A
Sales Q2Q%86.39%
Revenue Next Year104.68%
Revenue Next 2Y135.4%
Revenue Next 3Y105.19%
Revenue Next 5Y70.69%
EBIT growth 1Y-10.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.05%
EBIT Next 3Y15.79%
EBIT Next 5YN/A
FCF growth 1Y3.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.33%
OCF growth 3YN/A
OCF growth 5YN/A

AGIOS PHARMACEUTICALS INC / AGIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AGIOS PHARMACEUTICALS INC (AGIO) stock?

ChartMill assigns a fundamental rating of 5 / 10 to AGIO.


What is the valuation status of AGIOS PHARMACEUTICALS INC (AGIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to AGIOS PHARMACEUTICALS INC (AGIO). This can be considered as Overvalued.


What is the profitability of AGIO stock?

AGIOS PHARMACEUTICALS INC (AGIO) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AGIOS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of AGIOS PHARMACEUTICALS INC (AGIO) is expected to grow by 5.2% in the next year.